WHO WE ARE
Celluminova is a life science startup company specializing in identification of cancer stem cells. Our first indication is for malignant gliomas (aggressive brain tumors).
THE GLIOMA STEM CELL PROBLEM
Glioma stem cells are believed to be major drivers of tumor recurrence and are resistant to chemotherapy and radiation. Currently, no methods exist to identify or target these cells in patients.
OUR SOLUTION
Celluminova has developed a molecule specifically targeting glioma stem cells. Our patented compound, p-HTMI, is intended for application during brain surgery. p-HTMI is a fluorescent molecule that illuminates glioma stem cells, enabling neurosurgeons to distinguish between healthy and cancerous tissue within minutes.
OUR COMMITMENT
Research suggests that failure to target glioma stem cells explains the poor survival of aggressive brain tumor patients. Therefore, the ability to specifically detect and remove these cells could potentially result in improved patient outcomes. The benefit of patients is our main focus.
Company Details
- Employees
- 12
- Address
- Linköping, Se
- in****@****nova.se
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- celluminova.se
- Keywords
- Cancer Stem cells, Fluorescent Molecule, Biotechnology, Glioblastoma, Glioma, Biomaterials, Life Science, Pharmaceutical, Clinical development.
- HQ
- Linköping
Celluminova Questions
Celluminova's website is celluminova.se
Celluminova's LinkedIn profile is https://se.linkedin.com/company/celluminova
Celluminova has
12 employees.
View email and phone details for 12
employees at Celluminova.
Celluminova's industry is
Biotechnology Research
Celluminova's top competitors are
Nordic Biomarker,
Arguseye,
Sigrid Therapeutics,
Bioreperia,
Invenesis,
Anocca,
Invivo Biosystems,
Dynamic Code,
Lead (Business Incubator),
Cordicity.
Celluminova's support email address is info@celluminova.se
Celluminova's categories are Biotechnology Research
